ATE488237T1 - Verfahren zur behandlung von abnormalem zellwachstum - Google Patents

Verfahren zur behandlung von abnormalem zellwachstum

Info

Publication number
ATE488237T1
ATE488237T1 AT06820997T AT06820997T ATE488237T1 AT E488237 T1 ATE488237 T1 AT E488237T1 AT 06820997 T AT06820997 T AT 06820997T AT 06820997 T AT06820997 T AT 06820997T AT E488237 T1 ATE488237 T1 AT E488237T1
Authority
AT
Austria
Prior art keywords
cell growth
abnormal cell
treating abnormal
treating
growth
Prior art date
Application number
AT06820997T
Other languages
German (de)
English (en)
Inventor
James Gail Christensen
Yahong Zou
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE488237T1 publication Critical patent/ATE488237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06820997T 2005-12-05 2006-11-23 Verfahren zur behandlung von abnormalem zellwachstum ATE488237T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74276605P 2005-12-05 2005-12-05
US86463706P 2006-11-07 2006-11-07
PCT/IB2006/003397 WO2007066187A2 (en) 2005-12-05 2006-11-23 Method of treating abnormal cell growth

Publications (1)

Publication Number Publication Date
ATE488237T1 true ATE488237T1 (de) 2010-12-15

Family

ID=38123250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820997T ATE488237T1 (de) 2005-12-05 2006-11-23 Verfahren zur behandlung von abnormalem zellwachstum

Country Status (21)

Country Link
US (1) US7825137B2 (xx)
EP (1) EP1959955B1 (xx)
JP (1) JP4619346B2 (xx)
KR (1) KR101026676B1 (xx)
AR (1) AR056832A1 (xx)
AT (1) ATE488237T1 (xx)
AU (1) AU2006323027B2 (xx)
BR (1) BRPI0619424B1 (xx)
CA (1) CA2632286C (xx)
CY (1) CY1110931T1 (xx)
DE (1) DE602006018354D1 (xx)
DK (1) DK1959955T3 (xx)
HK (1) HK1126121A1 (xx)
IL (1) IL191471A (xx)
NZ (1) NZ568654A (xx)
PL (1) PL1959955T3 (xx)
PT (1) PT1959955E (xx)
RU (1) RU2384331C2 (xx)
SI (1) SI1959955T1 (xx)
TW (1) TWI321050B (xx)
WO (1) WO2007066187A2 (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
PT1889836E (pt) * 2005-08-24 2013-08-28 Eisai R&D Man Co Ltd Novo derivado de piridina e derivado de pirimidina (3)
PT1963302E (pt) * 2005-12-05 2013-04-09 Pfizer Prod Inc Polimorfos de um inibidor de c-met/hgfr
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
EP2062886B1 (en) * 2006-08-23 2011-11-30 Eisai R&D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
US20100311972A1 (en) * 2008-02-18 2010-12-09 Mitsuo Nagai Method for producing phenoxypyridine derivative
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
WO2010064300A1 (ja) * 2008-12-02 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食道癌治療用組成物
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
SG182803A1 (en) 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
WO2011100502A1 (en) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
US8846931B2 (en) 2010-07-05 2014-09-30 Merck Patent Gmbh Bipyridyl derivatives
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
CA2829025A1 (en) * 2011-03-03 2012-09-07 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
ES2542647T3 (es) 2011-03-09 2015-08-07 Merck Patent Gmbh Derivados de pirido[2,3 b]pirazina y sus usos terapéuticos
CN103842353A (zh) * 2011-09-21 2014-06-04 苏州韬略生物科技有限公司 作为激酶抑制剂的吡啶化合物
LT2810937T (lt) 2012-01-31 2017-02-10 Daiichi Sankyo Company, Limited Piridono darinys
EP2822953B9 (en) 2012-03-06 2017-06-21 Pfizer Inc Macrocyclic derivatives for the treatment of proliferative diseases
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
EP3336181B1 (en) 2012-04-18 2022-01-12 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
CN103509008A (zh) * 2012-06-22 2014-01-15 康瑟特制药公司 吡唑取代的氨基-杂芳基化合物的衍生物
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
JP6259828B2 (ja) 2012-09-24 2018-01-10 ヴェンタナ メディカル システムズ， インク． 未分化リンパ腫キナーゼ（ａｌｋ）をマーカーとして使用する治療応答性非小細胞肺癌の同定法
CA2890006C (en) * 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
EA201201654A1 (ru) * 2012-12-28 2014-06-30 Ооо "Эн.Си.Фарм" Противоопухолевое средство (варианты)
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
US20160022661A1 (en) * 2013-03-13 2016-01-28 Ratiopharm Gmbh Dosage Form Comprising Crizotinib
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
JP6291179B2 (ja) * 2013-07-26 2018-03-14 関東化學株式会社 光学活性２級アルコールの製造方法
US20160214961A1 (en) * 2013-09-10 2016-07-28 Shilpa Medicare Limited Novel salts of crizotinib and their preparation
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
BR112017002827B1 (pt) 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd Derivado de quinolina altamente puro e método para produção do mesmo
MX2017010474A (es) 2015-02-25 2017-11-28 Eisai R&D Man Co Ltd Metodo para suprimir el amargor de un derivado de quinoleina.
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
US12066428B2 (en) * 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
DK4019019T3 (da) 2016-05-20 2024-05-06 Biohaven Therapeutics Ltd Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling
GB201616116D0 (en) * 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
CN108047231B (zh) * 2018-01-02 2020-02-11 江苏医药职业学院 [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
US20220354951A1 (en) 2019-08-02 2022-11-10 Onehealthcompany, Inc. Treatment of Canine Cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DK1255740T3 (da) 2000-02-16 2006-02-06 Neurogen Corp Substituerede arylpyraziner
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
NZ541861A (en) 2003-02-26 2009-05-31 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PT1784396E (pt) 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
PT1963302E (pt) * 2005-12-05 2013-04-09 Pfizer Prod Inc Polimorfos de um inibidor de c-met/hgfr

Also Published As

Publication number Publication date
TW200727899A (en) 2007-08-01
US20080300273A1 (en) 2008-12-04
TWI321050B (en) 2010-03-01
IL191471A (en) 2013-03-24
CY1110931T1 (el) 2015-06-10
BRPI0619424B1 (pt) 2022-02-08
PL1959955T3 (pl) 2011-04-29
DK1959955T3 (da) 2011-02-07
IL191471A0 (en) 2009-08-03
JP4619346B2 (ja) 2011-01-26
PT1959955E (pt) 2011-01-04
RU2384331C2 (ru) 2010-03-20
AR056832A1 (es) 2007-10-24
EP1959955B1 (en) 2010-11-17
KR20080072965A (ko) 2008-08-07
US7825137B2 (en) 2010-11-02
AU2006323027A1 (en) 2007-06-14
DE602006018354D1 (de) 2010-12-30
HK1126121A1 (en) 2009-08-28
CA2632286C (en) 2011-11-15
SI1959955T1 (sl) 2011-02-28
KR101026676B1 (ko) 2011-04-04
CA2632286A1 (en) 2007-06-14
JP2007153894A (ja) 2007-06-21
NZ568654A (en) 2012-02-24
AU2006323027B2 (en) 2012-08-02
WO2007066187A2 (en) 2007-06-14
BRPI0619424A2 (pt) 2011-10-04
WO2007066187A3 (en) 2008-01-17
RU2008122471A (ru) 2009-12-10
EP1959955A2 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
ATE488237T1 (de) Verfahren zur behandlung von abnormalem zellwachstum
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE494780T1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
DE602006007890D1 (de) Verfahren zur Optimierung von Kombikraftwerken/Kombiverarbeitungsanlagen
ATE446792T1 (de) Verfahren zur behandlung von sinuskopfschmerzen
DE602005012489D1 (de) Verfahren zur Abwasserbehandlung
ATE408604T1 (de) Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
DE502006002552D1 (de) Verfahren zum Überladen von Erntegut
DE60331479D1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
ATE544341T1 (de) Verfahren zur verbesserung des nematoden toleranten bzw. -resistenten pflanzenwachstums
DE602006009605D1 (de) Verfahren zur Bearbeitung von Turbinenelementen
EP1720574A4 (en) METHOD OF TREATING ABNORMAL CELL GROWTH USING C-MET AND M-TOR INHIBITORS
ATE523949T1 (de) Verfahren zur regelung von wechselrichtern
DE502005010287D1 (de) Verfahren zur hydrocyanierung
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
ZA200804777B (en) Method of treating abnormal cell growth
DE602008001180D1 (de) Vorrichtung und Verfahren zur Behandlung von Textilien
FI20050145A (fi) Menetelmä biomassan käsittelemiseksi
ATE438613T1 (de) Verfahren zur herstellung von anilinen
DE502006005110D1 (de) Verfahren und vorrichtung zur umsetzung von internnsnetzwerkes
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
DE602005015492D1 (de) Verbessertes verfahren zur aufreinigung von perindopril

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1959955

Country of ref document: EP